Mostrar el registro sencillo del ítem
Effect of diacerein on renal function and inflammatory cytokines in participants with type 2 diabetes mellitus and chronic kidney disease : a randomized controlled trial
dc.contributor.author | Piovesan, Fabiana | pt_BR |
dc.contributor.author | Tres, Glaucia Sarturi | pt_BR |
dc.contributor.author | Moreira, Leila Beltrami | pt_BR |
dc.contributor.author | Andrades, Michael Everton | pt_BR |
dc.contributor.author | Lisboa, Hugo Roberto Kurtz | pt_BR |
dc.contributor.author | Fuchs, Sandra Cristina Pereira Costa | pt_BR |
dc.date.accessioned | 2020-12-09T04:12:59Z | pt_BR |
dc.date.issued | 2017 | pt_BR |
dc.identifier.issn | 1932-6203 | pt_BR |
dc.identifier.uri | http://hdl.handle.net/10183/216279 | pt_BR |
dc.description.abstract | Diacerein seems to improve metabolic control and reduce inflammatory marker levels in individuals with type 2 diabetes mellitus (Type 2 DM), but for participants with chronic kidney disease (CKD) its effect is unknown. This study aimed to evaluate the effect of diacerein vs. placebo on urinary albumin/creatinine ratio (ACR), glomerular filtration rate (GFR), and inflammatory cytokines in type 2 DM participants with CKD. Blood pressure (BP) and metabolic control were secondary outcomes. This randomized, placebo-controlled, parallel trial of adjuvant treatment of type 2 DM with diacerein enrolled seventy-two participants with CKD, aged 30–80 years, with glycated hemoglobin levels from 53–97 mmol/mol (7.0– 11.0%), receiving angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and antidiabetic agents. Participants randomized to diacerein or placebo were followedup up to 90 days. Both groups had a marked reduction in ACR, but there was no effect on glomerular filtration rate. While the diacerein group had reduced TNF-α levels at the 75th percentile with a borderline significance (P = 0.05), there were no changes in the IL levels at the 75th percentile. Diacerein prevented the increase in blood glucose to the level observed in the placebo group (P = 0.04), improving metabolic control by 74%, reducing 24-hour diastolic BP, nighttime systolic and diastolic BP compared to the placebo group. In conclusion, among patients with type 2 DM and CKD, diacerein does not have an effect on ACR or GFR, but slows metabolic control deterioration and is associated with lower nighttime systolic and diastolic blood pressure | en |
dc.format.mimetype | application/pdf | pt_BR |
dc.language.iso | eng | pt_BR |
dc.relation.ispartof | PLoS ONE. San Francisco. Vol. 12, no. 10 (Oct. 2017), e0186554, 13 p. | pt_BR |
dc.rights | Open Access | en |
dc.subject | Diabetes mellitus tipo 2 | pt_BR |
dc.subject | Citocinas | pt_BR |
dc.subject | Inflamação | pt_BR |
dc.subject | Anti-inflamatórios | pt_BR |
dc.subject | Insuficiência renal crônica | pt_BR |
dc.title | Effect of diacerein on renal function and inflammatory cytokines in participants with type 2 diabetes mellitus and chronic kidney disease : a randomized controlled trial | pt_BR |
dc.type | Artigo de periódico | pt_BR |
dc.identifier.nrb | 001119146 | pt_BR |
dc.type.origin | Estrangeiro | pt_BR |
Ficheros en el ítem
Este ítem está licenciado en la Creative Commons License
-
Artículos de Periódicos (39333)Ciencias de la Salud (10580)